PolyPid to Participate in the Craig-Hallum 15th Annual Alpha Select Conference

PYPD 11.07.2024

Full Press ReleaseSEC FilingsOur PYPD Tweets

About Gravity Analytica

Recent News

  • 12.24.2024 - PolyPid Announces Positive Recommendation by DSMB to Continue Enrollment of Phase 3 SHIELD II Trial of D-PLEX₁₀₀ to 800 Patients with a Concurrent Private Placement of up to $41 Million
  • 12.11.2024 - PolyPid Announces Research and Development Collaboration with ImmunoGenesis Leveraging PLEX Technology to Enhance Cancer Immunotherapy
  • 11.29.2024 - PolyPid Announces Receipt of Nasdaq Notification of Minimum Stockholders’ Equity Non-Compliance

Recent Filings

  • 01.21.2025 - F-3 Registration statement by foreign private issuers
  • 01.17.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
  • 01.02.2025 - D Notice of Exempt Offering of Securities

PETACH TIKVA, Israel,Nov. 07, 2024(GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that the Company’s management will participate in investor meetings at the Craig-Hallum 15thAnnualAlpha Select ConferenceonNovember 19, 2024, inNew York, NY.

Investors interested in meeting with PolyPid should contact the conference representative directly.

About PolyPid

PolyPid Ltd.(Nasdaq:PYPD) is a late-stage biopharma company aiming to improve surgical outcomes. Through locally administered, controlled, prolonged-release therapeutics, PolyPid’s proprietary PLEX (Polymer-Lipid Encapsulation matriX) technology pairs with Active Pharmaceutical Ingredients (APIs), enabling precise delivery of drugs at optimal release rates over durations ranging from several days to months. PolyPid’s lead product candidate D-PLEX100is in Phase 3 clinical trial for the prevention of abdominal colorectal surgical site infections. In addition, the Company is currently in preclinical stages to test the efficacy of OncoPLEX for the treatment of solid tumors, beginning with glioblastoma.

For additional Company information, please visithttp://www.polypid.comand follow us onTwitterandLinkedIn.

Contacts:PolyPid Ltd.Ori WarshavskyCOO – US908-858-5995IR@Polypid.com

Investors:Brian RitchieLifeSci Advisors212-915-2578britchie@lifesciadvisors.com

Primary Logo

Source: PolyPid Ltd.

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com